Loading...
Loading...
SNGX| Name | Value |
|---|---|
| Revenues | 2.3K |
| Cost of Revenue | 3.9K |
| Gross Profit | -1.6K |
| Operating Expense | 1,743.1K |
| Operating I/L | -1,747.0K |
| Other Income/Expense | 100.2K |
| Interest Income | 0.0K |
| Pretax | -1,612.7K |
| Income Tax Expense | 31.8K |
| Net Income/Loss | -1,644.5K |
Soligenix, Inc. is a late-stage biopharmaceutical company specializing in developing and commercializing products for rare diseases. The company operates in two segments: Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment focuses on developing novel therapies such as SGX301 and SGX942 for the treatment of cutaneous T-cell lymphoma and inflammatory diseases, respectively. Additionally, it offers proprietary formulations for gastrointestinal disorders and psoriasis treatment. The Public Health Solutions segment is involved in the development of vaccine candidates for diseases such as ricin toxin, antibiotic-resistant infections, and COVID-19 prevention.
